Joseph H. Phillips
22Patents
7h-index
29Co-inventors
69Inventor score
Filing activity: Oct 7, 1983 → Jun 19, 2015
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US4599304A | Method for monitoring activated cell subpopulations | Emerging Cross-Sectional Technologies | 17 | Expired |
| US5811284A | Nucleic acids encoding kp43 protein and antigenic fragments thereof | Human Necessities | 17 | Expired |
| US5124251A | CD3 .zeta. co-associated complex on CD16.sup.- NK cells | Chemistry; Metallurgy | 13 | Expired |
| US6416973B1 | Nucleic acids encoding mammalian cell membrane protein MDL-1 | Chemistry; Metallurgy | 12 | Expired |
| US6140076A | Ig superfamily `dlair` receptors expressed in monocytes | Chemistry; Metallurgy | 11 | Expired |
| US6953843B2 | Antibodies and fragments thereof to MDL-1 protein | Chemistry; Metallurgy | 10 | Expired |
| US6479638B1 | Antibodies that specifically bind DNAX leukocyte associated immunoglobulin-like receptor | Chemistry; Metallurgy | 10 | Expired |
| US7319140B2 | Binding compounds to DAP12 proteins | Chemistry; Metallurgy | 7 | Expired |
| US8212008B2 | Antibodies to CD200R | Chemistry; Metallurgy | 7 | Active |
| US7332574B2 | MDL-1 polypeptides | Chemistry; Metallurgy | 7 | Expired |
| US8153134B2 | Anti-MDL-1 antibodies | Chemistry; Metallurgy | 6 | Active |
| US5041289A | Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells | Human Necessities | 5 | Expired |
| US9827309B2 | Treating cancer with a combination of a PD-1 antagonist and dinaciclib | Chemistry; Metallurgy | 5 | Active |
| US4895796A | Identification of NK cells and cytotoxic T lymphocytes | Emerging Cross-Sectional Technologies | 4 | Expired |
| US5965401A | Purified mammalian NK antigens and related reagents | Chemistry; Metallurgy | 3 | Expired |
| US5770387A | Antibodies to mammalian NK antigens and uses | Emerging Cross-Sectional Technologies | 2 | Expired |
| US7999078B2 | Antibodies that bind DNAX leukocyte associated immunoglobulin-like receptor | Emerging Cross-Sectional Technologies | 2 | Active |
| US8236309B2 | Use of bispecific antibodies to regulate immune responses | Human Necessities | 1 | Active |
| US7659093B2 | DAP12 nucleic acids | Chemistry; Metallurgy | 1 | Active |
| US9284377B2 | MDL-1 ligand | Physics | 0 | Active |
| US8263070B2 | Methods of modulating CD200 receptors | Chemistry; Metallurgy | 0 | Active |
| US8178094B2 | Methods for inhibiting tumor growth or reducing metastatic burden in a subject by administering FDF03 antibodies | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.